Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology

 
• By Joseph Haas

Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.

Merck KGaA will call on Caris's AI capabilities in cancer ADC development

More from Deals

More from Business